MedDRA preferred term · leaking urine

Urinary incontinence: adverse event reports recording this term

29,113 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

29,113
reports recording the term: 0.1% of all reports; 1,331
reports, 12 months to June 2026: 1,548 in the 12 months before; 74.6%
marked serious by the reporter: 57.4% across all reports; 5%
record death among outcomes, as reported: 9.1% across all reports

29,113 reports in FDA's adverse event database record the MedDRA term "Urinary incontinence" (in plain words, leaking urine): 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

1,331 reports recorded it in the 12 months to June 2026, down 14% from 1,548 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 74.6% are marked serious, 5% include death among the outcomes and 36.1% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Tysabri, Avonex and Humira. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Tysabri	Integrin receptor antagonist	839	0.5%
Avonex	Interferon beta	705	0.6%
Humira	—	581	0.1%
Myrbetriq	beta3-Adrenergic agonist	579	3%
Gilenya	Sphingosine 1-phosphate receptor modulator	517	0.6%
Tecfidera	—	428	0.4%
Ocrevus	CD20-directed cytolytic antibody	403	0.8%
Lyrica	—	396	0.3%
Ampyra	Potassium channel blocker	362	0.6%
Risperidone	Atypical antipsychotic	362	0.8%
Rebif	Interferon beta	355	0.8%
Fosamax	Bisphosphonate	329	0.9%
Vesicare	—	304	2.4%
Enbrel	Tumor necrosis factor blocker	273	0%
Aubagio	Pyrimidine synthesis inhibitor	272	0.7%
Methotrexate	Folate analog metabolic inhibitor	272	0.1%
Gabapentin	Anti-epileptic agent	248	0.3%
Omeprazole	Proton pump inhibitor	248	0.4%
Abilify	Atypical antipsychotic	241	0.4%
Olanzapine	Atypical antipsychotic	235	0.5%
Clozapine	Atypical antipsychotic	233	0.3%
Xyrem	Central nervous system depressant	222	0.4%
Risperdal	Atypical antipsychotic	221	0.4%
Aripiprazole	Atypical antipsychotic	213	0.7%
Quetiapine	Atypical antipsychotic	212	0.4%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Atypical antipsychotic	2,676	0.4%	0.2%
Proton pump inhibitor	1,299	0.3%	0.2%
Interferon beta	1,140	0.6%	0.6%
Integrin receptor antagonist	916	0.4%	0.3%
Corticosteroid	885	0.1%	0%
beta3-Adrenergic agonist	811	3%	3%
Anti-epileptic agent	787	0.3%	0.2%
CD20-directed cytolytic antibody	746	0.2%	0.1%
Serotonin reuptake inhibitor	746	0.3%	0.2%
Opioid agonist	701	0.1%	0.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.1%18

2 to 111.7%486

12 to 171.1%328

18 to 4412.3%3,569

45 to 6423.1%6,733

65 to 7414.7%4,270

75 and over14%4,089

Age not given33%9,620

Patient sex

Female60.1%17,507

Male33.4%9,714

Not given6.5%1,892

Grey bar: all 20,646,523 reports in the database. 58.6% of these reports give the United States as the country.

Questions about "Urinary incontinence"

What does "Urinary incontinence" mean in an adverse event report?

In plain language: leaking urine. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record urinary incontinence?

29,113 reports through June 2026 (0.1% of all reports), 1,331 of them in the latest 12 months.

Which drugs appear most often in these reports?

Tysabri (839), Avonex (705), Humira (581), Myrbetriq (579) and Gilenya (517). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.